Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Operating Leases (2019 - 2026)

Protara Therapeutics' Operating Leases history spans 8 years, with the latest figure at $3.1 million for Q1 2026.

  • Quarterly Operating Leases fell 27.68% to $3.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.1 million through Mar 2026, down 27.68% year-over-year, with the annual reading at $2.1 million for FY2025, 36.98% down from the prior year.
  • Operating Leases came in at $3.1 million for Q1 2026, up from $2.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $6.2 million in Q1 2022 to a low of $2.1 million in Q4 2025.
  • The 5-year median for Operating Leases is $4.2 million (2024), against an average of $4.4 million.
  • Year-over-year, Operating Leases soared 532.44% in 2022 and then plummeted 36.98% in 2025.
  • Protara Therapeutics' Operating Leases stood at $5.5 million in 2022, then dropped by 17.98% to $4.5 million in 2023, then decreased by 25.09% to $3.4 million in 2024, then plummeted by 36.98% to $2.1 million in 2025, then skyrocketed by 44.4% to $3.1 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Operating Leases are $3.1 million (Q1 2026), $2.1 million (Q4 2025), and $2.4 million (Q3 2025).